Xiao-Hang Liu1, Jia-Yu Shi2, Xiao-Jin Feng1, Dong-Cai Feng1, Lin Wang3, Hai-Yu Pang4, Hong-Zhi Xie1, Fang-Fei Wang1, Jeffrey Hsu1, Fu-Wei Jia1, Wei Chen1. 1. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. 2. Department of Cardiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Jiangsu 226001, China. 3. Division of Cardiac imaging, St. Francis Hospital Heart Center, Long Island, NY, USA. 4. Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100730, China.
Abstract
BACKGROUND: Differences in short-term and 1-year outcomes of percutaneous edge-to-edge mitral repair between patients with functional and degenerative mitral regurgitation (MR) remain unclear. We performed a systematic review and meta-analysis to investigate the safety and efficacy of MitraClip (MC) in patients with different MR etiologies. METHODS: This study systematically searched three common databases for studies on MC therapy until November 2017. The studies meeting the standard inclusion criteria were included. The data at baseline, short-term and 1-year clinical and echocardiographic outcomes were obtained and analyzed. All data were checked by another reviewer. RESULTS: Thirteen studies totalling 2,351 patients investigating the short-term and 1-year outcomes of MC in patients with functional MR (FMR) versus degenerative MR (DMR) were included for further analysis. FMR patients presented a higher risk profile at baseline. There was no difference in short-term outcomes between DMR and FMR for post-procedural MR grade 0-2 (76.8% vs. 77.1%; P=0.428), mean trans-mitral gradient (3.92 vs. 3.50 mmHg; P=0.098), 30-day mortality rate (0.05% vs. 0.03%; P=0.118) and 30-day NYHA I-II (85.3% vs. 78.7%; P=0.211). FMR patients had a higher rate of acute procedural success compared to the DMR patient group (91.2% vs. 95.2%; P=0.016). A greater portion of DMR patients implanted two or more MCs than the FMR patients (41.4% vs. 35.7%; P=0.043). For the 1-year outcomes, no difference was found in the mortality rate (13.0% vs. 15.2%; P=0.268) and proportion of patients with post-procedural MR grades 0-2 (75.0% vs. 80.7%; P=0.106). CONCLUSIONS: Despite a higher risk profile in FMR patients, the short-term and 1-year outcomes were not significantly different. We conclude that MC therapy is similar between FMR and DMR patients until 1-year follow-up. Large randomized trials are warranted to fully and further assess the clinical impact of the procedure in these two MR etiologies over a longer period of time.
BACKGROUND: Differences in short-term and 1-year outcomes of percutaneous edge-to-edge mitral repair between patients with functional and degenerative mitral regurgitation (MR) remain unclear. We performed a systematic review and meta-analysis to investigate the safety and efficacy of MitraClip (MC) in patients with different MR etiologies. METHODS: This study systematically searched three common databases for studies on MC therapy until November 2017. The studies meeting the standard inclusion criteria were included. The data at baseline, short-term and 1-year clinical and echocardiographic outcomes were obtained and analyzed. All data were checked by another reviewer. RESULTS: Thirteen studies totalling 2,351 patients investigating the short-term and 1-year outcomes of MC in patients with functional MR (FMR) versus degenerative MR (DMR) were included for further analysis. FMR patients presented a higher risk profile at baseline. There was no difference in short-term outcomes between DMR and FMR for post-procedural MR grade 0-2 (76.8% vs. 77.1%; P=0.428), mean trans-mitral gradient (3.92 vs. 3.50 mmHg; P=0.098), 30-day mortality rate (0.05% vs. 0.03%; P=0.118) and 30-day NYHA I-II (85.3% vs. 78.7%; P=0.211). FMR patients had a higher rate of acute procedural success compared to the DMR patient group (91.2% vs. 95.2%; P=0.016). A greater portion of DMR patients implanted two or more MCs than the FMR patients (41.4% vs. 35.7%; P=0.043). For the 1-year outcomes, no difference was found in the mortality rate (13.0% vs. 15.2%; P=0.268) and proportion of patients with post-procedural MR grades 0-2 (75.0% vs. 80.7%; P=0.106). CONCLUSIONS: Despite a higher risk profile in FMR patients, the short-term and 1-year outcomes were not significantly different. We conclude that MC therapy is similar between FMR and DMR patients until 1-year follow-up. Large randomized trials are warranted to fully and further assess the clinical impact of the procedure in these two MR etiologies over a longer period of time.
Authors: Paul A Grayburn; Elyse Foster; Chithra Sangli; Neil J Weissman; Joseph Massaro; Donald G Glower; Ted Feldman; Laura Mauri Journal: Circulation Date: 2013-09-06 Impact factor: 29.690
Authors: Francesco Maisano; Olaf Franzen; Stephan Baldus; Ulrich Schäfer; Jörg Hausleiter; Christian Butter; Gian Paolo Ussia; Horst Sievert; Gert Richardt; Julian D Widder; Tiziano Moccetti; Wolfgang Schillinger Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: Pak Hei Chan; Hoi Lam She; Eduardo Alegria-Barrero; Neil Moat; Carlo Di Mario; Olaf Franzen Journal: Circ J Date: 2012-07-03 Impact factor: 2.993
Authors: Patrick L Whitlow; Ted Feldman; Wes R Pedersen; D Scott Lim; Robert Kipperman; Richard Smalling; Tanvir Bajwa; Howard C Herrmann; John Lasala; James T Maddux; Murat Tuzcu; Samir Kapadia; Alfredo Trento; Robert J Siegel; Elyse Foster; Donald Glower; Laura Mauri; Saibal Kar Journal: J Am Coll Cardiol Date: 2012-01-10 Impact factor: 24.094
Authors: Rodrigo Mendirichaga; Vikas Singh; Vanessa Blumer; Manuel Rivera; Alex P Rodriguez; Mauricio G Cohen; William W O'Neill; Sammy Elmariah Journal: Am J Cardiol Date: 2017-05-30 Impact factor: 2.778
Authors: Miriam Puls; Tobias Tichelbäcker; Annalen Bleckmann; Mark Hünlich; Katrin von der Ehe; Bo Eric Beuthner; Karin Rüter; Tim Beißbarth; Ralf Seipelt; Friedrich Schöndube; Gerd Hasenfuß; Wolfgang Schillinger Journal: EuroIntervention Date: 2014 Impact factor: 6.534